Table 3.
Percentage of adults under active treatment for obstructive airway diseases with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥5 EU/mL and antibody GMCs by timepoint (according-to-protocol cohort).
| Antibody | Timepoint | N | Seropositivity rate (≥5 EU/mL), % (95% CI) | GMC, EU/mL (95% CI) |
|---|---|---|---|---|
| Anti-PT | Pre | 209 | 58.4 (51.4; 65.1) | 7.4 (6.4; 8.6) |
| Post | 209 | 95.7 (92.0; 98.0) | 66.9 (56.3; 79.5) | |
| Anti-FHA | Pre | 208 | 96.6 (93.2; 98.6) | 44.9 (38.1; 52.9) |
| Post | 206 | 100 (98.2; 100) | 796.3 (683.3; 927.9) | |
| Anti-PRN | Pre | 208 | 70.7 (64.0; 76.8) | 13.1 (10.7; 16.1) |
| Post | 208 | 98.1 (95.1: 99.5) | 307.0 (241.9; 389.7) |
PT, pertussis toxoid; FHA, filamentous hemagglutinin; PRN, pertactin; EU, enzyme-linked immunosorbent assay units; GMC, geometric mean antibody concentration; N, number of adults with available results; CI, confidence interval; pre, pre-vaccination; post, 1 month post-vaccination.